ORIC’s Redwood-1 trial for enozertinib will test drug against osimertinib or afatinibNov 16Regulatory decisionafatinibAstraZenecaUpdated
Bicara reaches substantial enrollment in HPV-negative head and neck cancer trialNov 9Quarterly updateArriVent BioPharma, Inc.Bicara Therapeutics